Blockchain Registration Transaction Record
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. for Q3 2024
Stonegate Capital Partners provides an update on Bio-Path Holdings, Inc. for Q3 2024, emphasizing the company's innovative drug candidates and breakthrough technology in cancer treatment. With a strong IP position and strategic relationships, Bio-Path is poised for success and potential growth in the biopharmaceutical industry.

This news highlights Bio-Path Holdings' innovative approach to cancer treatment, showcasing its promising drug candidates and breakthrough technology. The company's strong IP position and strategic relationships position it as a key player in the biopharmaceutical industry, with potential for significant growth and advancements in cancer therapeutics.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0x15a0718b76b5d06fca0e47ee5198c5589d0ddf60216c2fbcdd4603e9f138ffe9 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | lambhfih-c07c6b8f16a287529171b346889abbb8 |